Application of lymph node dissection in intrahepatic cholangiocarcinoma

Abstract

Abstract: Intrahepatic cholangiocarcinoma is the second common primary malignant tumors of the liver with high degree of malignancy, and surgery is the only effective radical treatment. This tumor has a poor prognosis and a high risk of postoperative recurrence, and its risk factors are diverse. Lymph node metastasis is one of the most important risk factors. As one of the main purposes of defining N staging, regional lymph node dissection is also recommended in all guidelines as a routine surgical procedure. However, the prognostic value of lymph node dissection is still unclear, and its indications and scope of dissection are still controversial. Therefore, this article combines the literature to carry on the comprehensive review in this aspect.

Key words: Lymph node dissection, Intrahepatic cholangiocarcinoma, Surgery

Hu Hanjie, Huang Zhen, Zhao Hong. Application of lymph node dissection in intrahepatic cholangiocarcinoma[J]. Electronic Journal of Liver Tumor, 2020, 7(4): 13-16.

References

[1] EL-DIWANY R, PAWLIK T M, EJAZ A.Intrahepatic Cholangiocarcinoma[J].Surg Oncol Clin N Am, 2019, 28(4):587-599.
[2] AMINI N, EJAZ A, SPOLVERATO G, et al.Temporal trends in liver-directed therapy of patients with intrahepatic cholangiocarcinoma in the United States: a population-basedanalysis[J]. J Surg Oncol, 2014, 110(2):163-170.
[3] CILLO U, FONDEVILA C, DONADON M, et al. Surgery for cholangiocarcinoma[J]. Liver Int, 2019, 39 Suppl 1:143-155.
[4] MAVROS M N, ECONOMOPOULOS K P, ALEXIOU V G, et al.Treatment and Prognosis for Patients With Intrahepatic Cholangiocarcinoma:Systematic Review and Meta-analysis[J]. JAMA Surg, 2014, 149(6):565-574.
[5] RAOOF M, DUMITRA S, ITUARTE P, et al.Development and Validation of a Prognostic Score for Intrahepatic Cholangiocarcinoma[J]. JAMA Surg, 2017, 152(5):e170117.
[6] MA C H, HWANG D W, SONG K B, et al.Prognostic factors predicting survival rate over 10 years of patients with intrahepatic cholangiocarcinoma after hepatic resection[J]. Ann Surg Treat Res, 2020, 98(3):116-123.
[7] OHTA S, MORINE Y, IMURA S, et al.Carbohydrate Antigen 19-9 Is a Prognostic Factor Which Correlates With HDAC1 and HIF-1α for Intrahepatic Cholangiocarcinoma[J]. Anticancer Res, 2019, 39(11):6025-6033.
[8] SPOLVERATO G, KIM Y, ALEXANDRESCU S, et al.Management and Outcomes of Patients with Recurrent Intrahepatic Cholangiocarcinoma Following Previous Curative-Intent Surgical Resection[J]. Ann Surg Oncol, 2016, 23(1):235-243.
[9] SAHARA K, TSILIMIGRAS D I, MEHTA R, et al.A novel online prognostic tool to predict long-term survival after liver resection for intrahepatic cholangiocarcinoma:The "metro-ticket" paradigm[J]. J Surg Oncol, 2019, 120(2):223-230.
[10] SPOLVERATO G, KIM Y, EJAZ A, et al.Conditional Probability of Long-term Survival After Liver Resection for Intrahepatic Cholangiocarcinoma:A Multi-institutional Analysis of 535 Patients[J]. JAMA Surg, 2015, 150(6):538-545.
[11] 陆巍, 汤朝晖, 全志伟. 肝内胆管癌淋巴结清扫相关问题的探讨[J]. 中华外科杂志, 2019, 57(4):247-252.
[12] KITAGAWA Y, NAGINO M, KAMIYA J, et al.Lymph node metastasis from hilar cholangiocarcinoma: audit of 110 patients who underwent regional and paraaortic node dissection[J], Ann. Surg.2001, 233(3):385-392.
[13] NCCN. The NCCN Hepatobiliary Cancers Clinical Practice Guidelines in Oncology (Version 4.2020) [EB/OL]. Fort Washington: NCCN,2020[2020-06-19]. https://www.nccn.org/store/login/login.aspx?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf.
[14] WEBER S M, RIBERO D, O'REILLY E M, et al. Intrahepatic cholangiocarcinoma:expert consensus statement[J]. HPB (Oxford), 2015, 17(8):669-680.
[15] LEE A J, CHUN Y S.Intrahepatic cholangiocarcinoma:the AJCC/UICC 8th edition updates[J]. Chin Clin Oncol, 2018, 7(5):52.
[16] ZHANG X F, CHAKEDIS J, BAGANTE F, et al.Trends in use of lymphadenectomy in surgery with curative intent for intrahepatic cholangiocarcinoma[J]. Br J Surg, 2018, 105(7):857-866.
[17] WU L, TSILIMIGRAS D I, PAREDES A Z, et al.Trends in the Incidence, Treatment and Outcomes of Patients with Intrahepatic Cholangiocarcinoma in the USA: Facility Type is Associated with Margin Status, Use of Lymphadenectomy and Overall Survival[J]. World J Surg, 2019, 43(7):1777-1787.
[18] YOH T, CAUCHY F, LE ROY B, et al.Prognostic value of lymphadenectomy for long-term outcomes in node-negative intrahepatic cholangiocarcinoma:A multicenter study[J]. Surgery, 2019, 166(6):975-982.
[19] GROOT KOERKAMP B, WIGGERS J K, ALLEN P J, et al.Recurrence Rate and Pattern of Perihilar Cholangiocarcinoma after Curative Intent Resection[J]. J Am Coll Surg, 2015, 221(6):1041-1049.
[20] CHAN K M, TSAI C Y, YEH C N, et al.Characterization of intrahepatic cholangiocarcinoma after curative resection:outcome, prognostic factor, and recurrence[J]. BMC Gastroenterol, 2018, 18(1):180.
[21] GIL E, JOH J W, PARK H C, et al.Predictors and patterns of recurrence after curative liver resection in intrahepatic cholangiocarcinoma, for application of postoperative radiotherapy:a retrospective study[J]. World J Surg Oncol, 2015, 13:227.
[22] NAKAGAWA T, KAMIYAMA T, KURAUCHI N, et al.Number of lymph node metastases is a significant prognostic factor in intrahepatic cholangiocarcinoma[J]. World J Surg, 2005, 29(6):728-733.
[23] KIM S H, HAN D H, CHOI G H, et al.Oncologic Impact of Lymph Node Dissection for Intrahepatic Cholangiocarcinoma:a Propensity Score-Matched Study[J]. J Gastrointest Surg, 2019, 23(3):538-544.
[24] MIYATA T, YAMASHITA Y I, YAMAO T, et al.Clinical Benefits of Lymph Node Dissection in Intrahepatic Cholangiocarcinoma: A Retrospective Single-institution Study[J]. Anticancer Res, 2017, 37(5):2673-2677.
[25] TSUJI T, HIRAOKA T, KANEMITSU K, et al.Lymphatic spreading pattern of intrahepatic cholangiocarcinoma[J]. Surgery, 2001, 129(4):401-407.
[26] ALOIA T.AJCC Cancer Staging Manual, 8th,Int rahepatic Bile Ducts[M], 2018:295-302.
[27] MA W J, WU Z R, HU H J, et al.Extended Lymphadenectomy Versus Regional Lymphadenectomy in Resectable Hilar Cholangiocarcinoma[J]. J Gastrointest Surg. 2020, 24(7):1619-1629.
[28] BAGANTE F, SPOLVERATO G, WEISS M, et al.Assessment of the Lymph Node Status in Patients Undergoing Liver Resection for Intrahepatic Cholangiocarcinoma: the New Eighth Edition AJCC Staging System[J]. J Gastrointest Surg.2018, 22(1):52-59.
[29] GUGLIELMI A, RUZZENENTE A, CAMPAGNARO T, et al.Patterns and prognostic significance of lymph node dissection for surgical treatment of perihilar and intrahepatic cholangiocarcinoma[J]. J Gastrointest Surg, 2013, 17(11):1917-1928.
[30] LEE G C, GAMBLIN T C, FONG Z V, et al.Facility Type is Associated with Margin Status and Overall Survival of Patients with Resected Intrahepatic Cholangiocarcinoma[J]. Ann Surg Oncol, 2019, 26(12):4091-4099.
[31] 魏妙艳, 张园园, 耿智敏,等. 肝内胆管癌临床病理特征及淋巴结转移特点的多中心回顾性研究(附1321例报告)[J]. 中华消化外科杂志,2018, 17(3): 257-265
[32] SEO S, HATANO E, HIGASHI T, et al.Fluorine-18 fluorodeoxyglucose positron emission tomography predicts lymph node metastasis, P-glycoprotein expression, and recurrence after resection in mass-forming intrahepatic cholangiocarcinoma[J]. Surgery, 2008, 143(6):769-777.
[33] ZHU Y, MAO Y, CHEN J, et al.Preoperative Computed Tomography Features of Intrahepatic Cholangiocarcinoma for Predicting Lymph Node Metastasis and Overall Survival[J]. J Comput Assist Tomogr, 2019, 43(5):729-735.
[34] SQUIRES M H, CLOYD J M, DILLHOFF M, et al.Challenges of surgical management of intrahepatic cholangiocarcinoma[J]. Expert Rev Gastroenterol Hepatol, 2018, 12(7):671-681.
[35] SAHARA K, TSILIMIGRAS D I, MERATH K, et al.Therapeutic Index Associated with Lymphadenectomy Among Patients with Intrahepatic Cholangiocarcinoma: Which Patients Benefit the Most from Nodal Evaluation?[J]. Ann Surg Oncol, 2019, 26(9):2959-2968.
[36] SAHARA K, TSILIMIGRAS D I, PAWLIK T M.ASO Author Reflections: Which Patients Benefit the Most From Lymphadenectomy During Resection for Intrahepatic Cholangiocarcinoma?[J]. Ann Surg Oncol, 2019, 26(9):2969-2970.